secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001576280-25-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q4 revenue up 30% to $201.8M; 2025 revenue guidance $850-860M, convertible debt exchanged
--------------------------------------------------------------------------------

- Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).
- Q4 2024 revenue $201.8M (+30% YoY); net loss $111M ($0.90 loss per share); non-GAAP net loss $77.3M ($0.62 loss per share).
- Completed convertible debt exchange: issued $600M 1.25% 2031 notes, retiring $659.3M of 0% 2027 notes; also repurchased $45M of common stock.
- 2025 guidance: revenue $850-860M (15-16% growth); oncology clinical volume growth expected to accelerate to ~25%; screening revenue $25-30M on 45-50K Shield tests.
- Free cash flow burn improved to $275M in 2024; expects $225-235M in 2025; Guardant Reveal received Medicare coverage for CRC surveillance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000043/0001576280-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000043/gh-20250220.htm
  HTML page:      https://secwatch.observer/filing/0001576280-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer